Abstract
INTRODUCTION
The degeneration of cortical layers is associated with cognitive decline in Alzheimer’s disease (AD). Current therapies for AD are not disease-modifying, and, despite substantial efforts, research and development for AD has faced formidable challenges. In addition, cellular senescence has emerged as a significant contributor to therapy resistance.
METHODS
Human iPSC-derived cortical neurons were cultured on microelectrode arrays to measure long-term potentiation (LTP) noninvasively. Neurons were treated with pathogenic amyloid-β (Aβ) to analyze senescence and response to therapeutic molecules.
RESULTS
Microphysiological recordings revealed Aβ dampened cortical LTP activity and accelerated neuronal senescence. Aging neurons secreted inflammatory factors previously detected in brain, plasma, and cerebral spinal fluid of AD patients, in which drugs modulated senescence-related factors.
DISCUSSION
This platform measures and records neuronal LTP activity in response to Aβ and therapeutic molecules in real-time. Efficacy data from similar platforms have been accepted by the FDA for neurodegenerative diseases, expediting regulatory submissions.
Highlights
This work developed a progerontic model of amyloid-β (Aβ)-driven cortical degeneration.
This work measured neuronal LTP and correlated function with aging biomarkers.
Aβ is a driver of neuronal senescence and cortical degeneration.
Molecules rescued neuronal function but did not halt Aβ-driven senescence.
Therapeutic molecules modulated secretion of inflammatory factors by aging neurons.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Leandro H. Gallo,
Nesar Akanda,
Kaveena Autar,
Aakash Patel,
Ian Cox,
Haley A. Powell,
Marcella Grillo,
Natali Barakat,
Dave Morgan,
Xiufang Guo,
James J. Hickman | July 30, 2024